Bioequivalence Evaluation of Immediate-Release Empagliflozin/Metformin Fixed-Dose Combination Tablets Under Fed Conditions in Healthy Mexican Subjects and Exploratory Analysis of Metformin Dose Proportionality
Abstract
Background/Objectives: Fixed-dose combinations (FDCs) improve therapeutic adherence in type 2 diabetes. These studies aimed to evaluate the pharmacokinetics and establish the bioequivalence of four immediate-release empagliflozin/metformin FDC formulations under fed conditions in healthy Mexican subjects. Methods: A total of 42 healthy volunteers per study (168 total) were enrolled in four randomized, open-label, two-way crossover, single-dose studies with a 14-day washout period. Formulations were administered orally under standardized fed conditions. Plasma concentrations of both drugs were quantified using a validated liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method. Results: Across all dose strengths, the 90% confidence intervals (CIs) for the geometric mean ratios of peak plasma concentration (Cmax) and area under the concentration-time curve (AUC0-t) for both empagliflozin and metformin were entirely within the 80.00-125.00% bioequivalence acceptance range. The specific 90% CIs for Cmax and AUC0-t were: Study A (5/850 mg): empagliflozin (90.18-103.16%; 94.37-101.81%), metformin (98.43-107.69%; 97.18-106.62%); Study B (12.5/500 mg): empagliflozin (91.94-102.77%; 93.38-98.51%), metformin (92.58-101.73%; 94.85-103.91%); Study C (12.5/850 mg): empagliflozin (95.47-107.74%; 95.34-101.25%), metformin (94.19-103.59%; 94.06-103.21%); and Study D (12.5/1000 mg): empagliflozin (94.53-107.10%; 98.13-105.66%), metformin (98.89-107.51%; 99.25-109.92%).…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 42 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.